Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Clascoterone is promising for hair loss, showing 24.5% improvement in satisfaction compared to placebo. Users consider it an alternative to finasteride, with concerns about absorption and side effects.

PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.

The user does not respond well to minoxidil and is seeking an alternative to Tretinoin to upregulate sulfurtransferase activity for hair loss treatment. No specific alternative treatments were mentioned.

A user reported positive results using 1mg finasteride for 11 weeks, with hair regrowth at the hairline, sides, and crown, and no side effects. They also added Nizoral shampoo to their routine.

GT20029 is discussed as a potential treatment for androgenetic hair loss by targeting androgen receptors, unlike finasteride which reduces DHT broadly. Concerns include its effectiveness, genetic variations in androgen receptors, and availability, with some skepticism about its potential as a true alternative.

The user is using 0.1% dutasteride, 1% minoxidil with 2% procapil and 0.005% caffeine in the morning, and 1% minoxidil with 2% procapil and 0.01% tretinoin at night. They are concerned about the solution vehicle's effectiveness in preventing systemic absorption and ensuring the products stay around the hair follicles.

The conversation is about a user obtaining a compounded treatment for hair loss, including 0.1% latanoprost, 0.2% melatonin, and 1% cetirizine. The user also uses 2.5 mg dutasteride, 5 mg minoxidil, and RU58841 daily, and is at Norwood 2.

Mixing clascoterone with minoxidil involves using 99% ethanol and propylene glycol. Users discuss the effectiveness and potential side effects of this DIY solution.

The conversation discusses experiences with Hair Stem Cell Transplantation (HST) for hair loss. Users also mention treatments like Minoxidil, finasteride, and RU58841.

Kintor is potentially pursuing a new hair loss treatment, KT-215, while users express skepticism about the speed and reliability of new product releases. There is a general sentiment that Chinese companies might be more promising in delivering timely solutions.

Concerns about the legitimacy of pyrilutamide solutions from Farmacia Tristaina due to low prices and lack of testing. Users suggest using Jano testing for product verification.

GT20029 and PP405 are discussed as potential alternatives or complements to finasteride for hair loss treatment. GT20029 is entering phase 3 trials, while PP405 is seen as promising for regrowing hair and possibly eliminating the need for other treatments.

Dr. Tsuji is giving online lectures about hair multiplication trials. Users express hope for a cure, but some are skeptical about its timeline.

Clascoterone results are anticipated to be released in fall 2026, possibly at the EADV conference. Users express skepticism and humor about the release date.

A user from Ireland is seeking topical dutasteride with trichosol, which is unavailable in Ireland, and is looking for European pharmacies that can provide it. Recommendations include pharmacies in Switzerland, Italy, Belgium, and Bucharest, with mixed reviews about Farmacia Parati in Italy.

The conversation is about using RU58841 for hair loss, discussing the stability of the powder form and the need for a carrier solution like KB or PG + ethanol. The user is advised to mix RU58841 with stemoxydine and store it properly, while also considering safety precautions.

SCUBE3 is a promising new molecule that can restart hair growth by reawakening dormant hair follicles. Users express skepticism about its availability timeline, with some hoping for release by 2026.

Koshine KX-826 has different versions, and the green version uses a plant-based carrier that may be less irritating for those sensitive to propylene glycol. Users report irritation with some versions of KX-826.

People are discussing the group buy and availability of KX-826 for hair loss treatment, with shipments expected around March-April. There is interest in finding more information and joining future group buys.

Finasteride, minoxidil, and derma rolling are currently the best treatments for hair loss. New treatments like TDM-105795, GT20029, PP405, HMI 115, Tsuji, Scube 3, RU, JW0061, Topilutamide, and verteporfin show promise but have uncertain timelines.

VDPHL-01 is essentially a slow-release oral minoxidil, which is already known to work for hair growth. The formulation includes other ingredients like Medrogestone, Valproic acid, Setipiprant, and Cetirizine, but their effectiveness and necessity are questioned.

RU58841 not working for hair loss after 10 months. Concerns about purity of experimental drugs.

The conversation is about a user's hair loss treatment regimen, which includes Dutasteride, oral Minoxidil, topical Dutasteride, Minoxidil sulfate, antioxidants, and various supplements. The user is also using a derma stamp and has paused Tretinoin due to a TCA peel recovery.

Everychem's solution, similar to PP405, has mixed results for hair regrowth, with some users reporting improvements and others seeing no change or worsening hair loss. Users are sharing experiences and updates to determine its effectiveness.

A user is seeking a titanium dioxide-free finasteride pill due to health concerns. They have not found a suitable supplier yet.

GT-20029 is discussed as a potential hair loss treatment, with concerns about its safety and systemic absorption compared to finasteride. Users express skepticism about its effectiveness and safety, noting that it may not surpass existing treatments like finasteride and minoxidil.

The conversation is about finding a safe carrier for topical antiandrogens like finasteride, kx-826, RU58841, and dutasteride to minimize systemic absorption and side effects. The user experiences side effects from these treatments and is seeking advice on carriers that reduce these effects.

A user is questioning the authenticity of a cheaper RU58841 product compared to other brands. Another user explains that RU58841 is a research chemical and suggests caution when purchasing such products.

Kintor Pharmaceutical's stock rise suggests potential positive news about Pyrilutamide, a topical anti-androgen. GT20029 may also compete with existing treatments like finasteride and dutasteride.

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.